1. Home
  2. CIVB vs PRME Comparison

CIVB vs PRME Comparison

Compare CIVB & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Civista Bancshares Inc.

CIVB

Civista Bancshares Inc.

HOLD

Current Price

$25.56

Market Cap

538.3M

Sector

Finance

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.42

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIVB
PRME
Founded
1884
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
538.3M
536.4M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
CIVB
PRME
Price
$25.56
$3.42
Analyst Decision
Buy
Buy
Analyst Count
5
6
Target Price
$26.60
$7.56
AVG Volume (30 Days)
51.4K
2.6M
Earning Date
04-22-2026
05-08-2026
Dividend Yield
2.90%
N/A
EPS Growth
31.34
18.18
EPS
0.72
N/A
Revenue
$19,023,000.00
$4,632,000.00
Revenue This Year
$14.88
$7.06
Revenue Next Year
$5.99
$47.01
P/E Ratio
$35.50
N/A
Revenue Growth
N/A
55.28
52 Week Low
$18.95
$1.29
52 Week High
$26.15
$6.94

Technical Indicators

Market Signals
Indicator
CIVB
PRME
Relative Strength Index (RSI) 58.66 54.33
Support Level $21.39 $3.15
Resistance Level $25.99 $3.97
Average True Range (ATR) 0.68 0.22
MACD 0.04 0.07
Stochastic Oscillator 70.21 84.30

Price Performance

Historical Comparison
CIVB
PRME

About CIVB Civista Bancshares Inc.

Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: